Why the study?
Anthracycline-treated childhood cancer survivors face a high risk of cardiotoxicity, but the cost-effectiveness of dexrazoxane for cardiotoxicity prevention in paediatric cancer patients has not been established.
Is dexrazoxane cost-effective for the prevention of anthracycline-related cardiotoxicity in children with sarcoma and haematologic malignancies?
Population
10,000 simulated patients with either sarcoma or haematologic malignancies
Comparison
Dexrazoxane treatment vs no dexrazoxane
Design
Cost-effectiveness simulation model
Authors
Loading...
Supports dexrazoxane in high-risk pediatric anthracycline recipients; extends RCT data with economic modeling across systems.
Is dexrazoxane cost-effective for the prevention of anthracycline-related cardiotoxicity in children with sarcoma and haematologic malignancies?
Dexrazoxane is highly cost-effective for preventing anthracycline-induced cardiotoxicity in pediatric patients with sarcoma or hematological malignancies across multiple European healthcare systems.
Dewilde et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: